These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28814431)

  • 1. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
    Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
    Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
    Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
    Hammer HB; Ødegård S; Syversen SW; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2010 Jan; 69(1):150-4. PubMed ID: 19095696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
    Nordal HH; Brokstad KA; Solheim M; Halse AK; Kvien TK; Hammer HB
    Arthritis Res Ther; 2017 Jan; 19(1):3. PubMed ID: 28081709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
    Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
    Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
    Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
    Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
    Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
    PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
    Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
    J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.
    Paulshus Sundlisæter N; Aga AB; Olsen IC; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
    Ann Rheum Dis; 2018 Oct; 77(10):1421-1425. PubMed ID: 29934373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
    Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
    Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
    García-Arias M; Pascual-Salcedo D; Ramiro S; Ueberschlag ME; Jermann TM; Cara C; Martín-Mola E; Balsa A
    Mol Diagn Ther; 2013 Feb; 17(1):49-56. PubMed ID: 23329363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.
    Acar A; Guzel S; Sarifakioglu B; Guzel EC; Guzelant AY; Karadag C; Kiziler L
    Clin Rheumatol; 2016 Nov; 35(11):2685-2692. PubMed ID: 27094943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.
    Hurnakova J; Hulejova H; Zavada J; Komarc M; Cerezo LA; Mann H; Vencovsky J; Pavelka K; Senolt L
    Clin Rheumatol; 2018 Aug; 37(8):2055-2062. PubMed ID: 29656372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis.
    Hammer HB; Haavardsholm EA; Kvien TK
    Scand J Rheumatol; 2008; 37(3):179-82. PubMed ID: 18465451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.